Abstract
SUMMARY Despite the efficacy of multimodality treatment for women with breast cancer, sustained locoregional control remains a significant issue. Efforts to identify effective targeted therapies for treatment of these patients have intensified in recent years. The PARP family of proteins represents one potential target. PARP-1 is a DNA repair enzyme that plays a critical role in base excision repair, homologous recombination, nonhomologous end joining and transcriptional regulation. In this review, we discuss the rationale for using PARP-1 inhibitors clinically, the role of PARP-1 in DNA damage repair and the potential clinical utility of using PARP-1 inhibitors as a radiosensitization strategy. We will also review the most relevant clinical trials using various PARP-1 inhibitors and the future of biomarker development to predict response to PARP-1 inhibition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
